Journal
WATER RESEARCH
Volume 42, Issue 17, Pages 4578-4588Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.watres.2008.08.006
Keywords
Activated sludge; Pharmaceuticals; Bacterial community structure; T-RFLP; 16S rRNA; Diversity
Funding
- Slovenian Research Agency [100008-210776]
- EU Structural Funds [3211-05-000183, 3211-05-000184]
Ask authors/readers for more resources
Concern is growing over contamination of the environment with pharmaceuticals because of their widespread use and incomplete removal during wastewater treatment, where microorganisms drive the key processes. The influence of pharmaceuticals on bacterial community structure in activated sludge was assessed in small-scale wastewater treatment bioreactors containing different concentrations (5, 50, 200 and 500 mu gL(-1)) of several commonly used pharmaceuticals (ibuprofen, naproxen, ketoprofen, diclofenac and clofibric acid). T-RFLP analyses of the bacterial 16S rRNA genes indicated a minor but consistent shift in the bacterial community structure in the bioreactor R50 supplied with pharmaceuticals at a concentration of 50 pg L-1, compared to the control reactor RO, which was operated without addition of pharmaceuticals. In the reactors operated with higher concentrations of pharmaceuticals, a greater structural divergence was observed. Bacterial community composition was further investigated by preparation of two clone libraries of bacterial 16S rRNA genes from reactors RO and R50. Most clones in both libraries belonged to the Betaproteo-bacteria, among which Thauera, Sphaerotilus, Ideonella and Acidovorax-related spp. dominated. Nitrite-oxidizing bacteria of the genus Nitrospira sp., which are key organisms for the second stage of nitrification in wastewater treatment plants, were found only in the clone library of the reactor without pharmaceuticals. In addition, diversity indices were calculated for the two clone libraries, indicating a reduced diversity of activated sludge bacterial community in the reactor supplied with 50 mu g L-1 of each of selected pharmaceuticals. (C) 2008 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available